Clinical Implications of Patient-Provider Agreements in Opioid Prescribing
| Autor: | Carl N. Kraus, R.G. McAllister, Frederick A. Curro, Alan Baldwin |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Patients Health Personnel MEDLINE Alternative medicine Certification Toxicology Drug Prescriptions Blueprint Completion rate medicine Humans Pharmacology (medical) Psychiatry Pharmacology United States Food and Drug Administration business.industry Chronic pain Service provider Legislation Drug medicine.disease United States Analgesics Opioid Family medicine Meta-analysis Education Medical Continuing business |
| Zdroj: | Current Drug Safety. 10:159-164 |
| ISSN: | 1574-8863 |
| DOI: | 10.2174/1574886309666140922095844 |
| Popis: | In June, 2012 the United States Food and Drug Administration (FDA) developed a "blueprint" for prescriber education as a means of directing Certified Medical Education (CME) activities that included content which would meet the regulatory requirements of the class-wide, longacting/ extended-release (LA-ER) opioid Risk Evaluation Mitigation Strategies (REMS). Within the blueprint is the suggested adoption of Patient-Provider Agreements (PPAs) to be used in association with opioid prescribing, but, to our knowledge, there have been no reported evaluations of the role played by opioid-agent PPAs in clinical practice, or of the perceptions of this regulatory mandate by clinicians. Therefore, we conducted a survey regarding PPA perceptions by opioid prescribers that was posted for five weeks on a well-trafficked online CME service provider (Medscape). Of the 1,232 respondents (reflecting a 99.5% completion rate), 52.4% treat acute or chronic pain with opioids. The survey identified an improvement of opioid safe-use education (21% of respondents) as the most frequently selected beneficial element of PPAs. Conversely, the challenges to adoption included time constraints (21% of physicians) as well as lack of evidence that PPAs will reduce drug misuse, and the lack of a uniform, patient-friendly PPA. Based on our survey, clinicians consider the PPA of potential value, but data regarding the utility of such an instrument are lacking. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|